113 results about "Blood Disorder" patented technology

The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist. The modified antibody can be used as a signal transduction agonist and, therefore, useful as a preventive and/or remedy for various diseases such as cancer, inflammation, hormone disorders and blood diseases.

Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

Methods of treating blood disorders are described.

Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and/or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.

Methods and compositions are disclosed to quantitatively measure in vivo blood vessel diameter, blood velocity, and other flow dynamics. Such methods and compositions can optimize therapeutic interventions designed to prevent or reduce the risk of cardiovascular and blood disorders. In one aspect, the methods and apparatus involve calculating blood vessel characteristics from a two dimensional image of a blood vessel in the conjunctiva of a subject's eye. In another aspect, a series of temporal images of a blood vessel are obtained to determine blood flow properties. The apparatus can include, for example, a biomicroscope, an illuminating light source and a high speed camera to acquire the series of temporal images with the data then analyzed by a programmed processor.

Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas compound with an NO group which does not form NO₂/NO_x in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO₂/NO_x in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite.

Pharmaceutical uses of glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation, thrombi formation.

This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds.

The invention describes methods for treating blood disorders or for treating the symptoms and/or complications associated with blood disorders by administering a therapeutically effective amount of at least one nitric oxide donor compound and optionally at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one therapeutic agent. The antioxidant is preferably a hydralazine compound or a pharmaceutically acceptable salt thereof. The nitric oxide donor compound is preferably N-hydroxy-L-arginine and/or isosorbide dinitrate and/or isosorbide mononitrate. The blood disorder is preferably sickle cell anemia. The complication resulting from a blood disorder is preferably pulmonary hypertension.

The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting cells (APCs), preferably provided as an intermixture. The APCs are modified to express immune modulating molecules. Immunization with the vaccine composition of present invention into a subject, induces the host immune system to respond and generate efficient immunity against either pre-existing disease or protect the host against the disease.

The present invention provides a method for treating hematological disorders such as anemia and thrombocytopenia, whereby a TPO mimetic peptide compound is administered using a specified dosing regimen. The dosing regimen involves the administration of the TPO mimetic peptide compound within a specified time frame surrounding administration of a chemotherapeutic agent. The dosing regimen also involves monitoring subject response in order to determine future course of treatment.

Provided herein are method of treating, ameliorating, or delaying at least one symptom of a genetic blood disorder, e.g. sickle cell disorder or thalassemia, in a patient in need thereof, comprising administering a therapeutically effective amount of a Jak2 inhibitor. Also provided in part is a method of reducing an enlarged spleen in a patient suffering from thalassemia, comprising administering a therapeutically effective amount of a Jak2 inhibitor.

The invention relates to a medicament for treating viral meningitis, in particular to a traditional Chinese medicine composition for treating viral meningitis, which is prepared from plant Chinese herbal medicines as raw materials. The medicament is characterized in that the raw materials for preparing active constituents comprise the following components of: 20-30 g of raw Astragalus mongholicus, 20-30 g of indigo naturalis, 10-20 g of red ginseng, 10-20 g of white paeony roots, 5-15 g of bighead atractylodes rhizome, 5-15 g of bamboo shavings, 5-15 g of bugbane, 5-15 g of the root of Chinese thorowax, 3-8 g of Pinellia ternate, 3-8 g of goldthread and 3-8 g of radix glycyrrhizae preparata. After being compounded, all raw materials bring out the best in each other so that the medicament has the effects of reinforcing Qi and raising Yang, regulating and nourishing spleens and stomachs, nourishing lungs to intensify exterior, reinforcing vital energy, treating blood disorders, activating blood and dissolving stasis, clearing heat and drying damp as well as purging intense heat and the like with the synergistic effect of a medicine effect, can treat both principal and secondary aspects of a disease without side effects, and has an obvious curative effect on viral meningitis caused by spleen and stomach Qi deficiency, sinking of middle Qi, deficient fire ascent and the like.